Can amitriptyline cause constipation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 1, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Amitriptyline Cause Constipation?

Yes, amitriptyline definitively causes constipation through its anticholinergic properties, and this is one of its most significant adverse effects that warrants specific clinical consideration and prophylactic management.

Mechanism and Clinical Evidence

Amitriptyline causes constipation through anticholinergic blockade of muscarinic receptors, which directly impairs gastrointestinal motility. 1 The FDA drug label explicitly lists constipation as an anticholinergic adverse effect of amitriptyline. 2

  • The constipating effect occurs across the entire dosing spectrum, from low doses (10 mg) to higher doses (150 mg). 1, 3
  • As a tertiary amine tricyclic antidepressant, amitriptyline has particularly strong anticholinergic properties compared to secondary amine tricyclics like desipramine or nortriptyline. 1

Clinical Significance and Severity

The British Society of Gastroenterology explicitly recommends that tricyclic antidepressants "are best avoided if constipation is a major feature" in IBS patients, indicating this is a clinically meaningful problem. 3

  • Constipation represents the most significant adverse effect of tricyclic antidepressants including amitriptyline, occurring frequently enough to warrant specific clinical consideration. 3
  • Serious complications can occur, including intestinal pseudo-obstruction, bowel obstruction, and even cecal perforation in severe cases. 2, 4
  • The FDA label lists paralytic ileus as a potential anticholinergic complication. 2

Prophylactic Management Strategy

When prescribing amitriptyline, prophylactic laxative therapy should be initiated, particularly in high-risk patients. 3

  • Stimulant laxatives (such as senna or bisacodyl) are recommended as prophylactic treatment. 5, 3
  • Polyethylene glycol (PEG) 17g with 8 oz water twice daily is an effective preventive measure. 5
  • Increase fluid intake and encourage physical activity when appropriate. 5, 3
  • Dietary interventions with adequate fiber intake for patients with sufficient fluid intake are recommended. 5

Treatment of Established Constipation

For established constipation on amitriptyline, titrate stimulant laxatives aggressively: bisacodyl 10-15 mg daily to three times daily. 5, 3

  • Aim for one non-forced bowel movement every 1-2 days. 5, 3
  • Add osmotic laxatives such as polyethylene glycol (1 capful/8 oz water twice daily) for persistent constipation. 5
  • Consider adding a prokinetic agent (e.g., metoclopramide 10-20 mg PO four times daily) for severe or refractory cases. 5
  • Peripherally acting μ-opioid receptor antagonists like methylnaltrexone (0.15 mg/kg subcutaneously every other day) may be considered for severe constipation. 5

Critical Pitfalls to Avoid

Do not use stool softeners (docusate) alone without stimulant laxatives, as they have no proven benefit for anticholinergic-induced constipation. 5, 3

  • Avoid adding psyllium or fiber supplements, as they are ineffective and may worsen symptoms in patients with reduced gastrointestinal motility. 5
  • Failing to anticipate and prophylactically treat constipation when initiating amitriptyline can lead to patient discomfort, medication discontinuation, and serious complications. 3
  • Rule out bowel obstruction with physical exam and consider abdominal x-ray if symptoms worsen despite treatment. 5, 3

Alternative Medication Selection

In patients with pre-existing constipation, amitriptyline should be avoided entirely or alternative agents with lower anticholinergic profiles should be selected. 3

  • Secondary amine tricyclics (desipramine, nortriptyline) may be better tolerated in patients with constipation-predominant conditions due to their lower anticholinergic effects. 1, 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Constipation Associated with Amitriptyline and Librax Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Clozapine-Associated Constipation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

Is Pristiq (desvenlafaxine) more likely to cause constipation than nortriptyline?
Is constipation more common with Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) or Bupropion (Wellbutrin)?
What is the incidence of constipation in patients undergoing amitriptyline (tricyclic antidepressant) and Librax (chlordiazepoxide and clidinium) therapy?
Is amitriptyline (tricyclic antidepressant) effective for treating poor bladder emptying (urinary retention)?
What is the best management for a vitally stable adult patient with schizophrenia on medication, presenting with recurrent abdominal distention and constipation, and found to have a dilated colon lumen without obstruction on imaging?
What is the recommended treatment regimen for acne vulgaris, covering mild‑to‑moderate disease, inflammatory lesions, hormonal acne in females, severe nodulocystic acne, and pregnancy considerations?
How should I evaluate and manage a 54‑year‑old diabetic woman with pancytopenia (no bleeding) who now has a draining abscess on her left shin?
What is the appropriate initial management for a 48‑year‑old woman with a history of plantar fasciitis and heel spur who now presents with great toe pain and normal foot radiographs?
In an elderly, immobile patient with diabetes, peripheral vascular disease, and chronic kidney disease who is hemodynamically stable, well‑nutrified, and has no uncontrolled coagulopathy or severe wound infection, is debridement of a sacral pressure ulcer considered a low‑risk procedure?
In a 28-year-old man with type 2 diabetes on metformin, empagliflozin (Jardiance) and tirzepatide (Zepbound) who has an A1c of 12 %, random glucose 311 mg/dL, mild ketonuria, normal bicarbonate and anion gap, eGFR 129 mL/min/1.73 m², triglycerides 525 mg/dL, HDL 27 mg/dL, LDL 86 mg/dL, and is asymptomatic, what are the appropriate management recommendations given his last follow‑up was 6–8 months ago?
A diabetic patient receiving linezolid for a shin soft‑tissue infection now has thrombocytopenia (platelet count 41 × 10⁹/L), anemia (hemoglobin 10 g/dL) and leukopenia (white‑blood‑cell count 2,300/µL). What is the most likely cause and how should the pancytopenia and infection be managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.